These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28570808)

  • 1. Development and Characterization of a Fluorescent Tracer for the Free Fatty Acid Receptor 2 (FFA2/GPR43).
    Hansen AH; Sergeev E; Pandey SK; Hudson BD; Christiansen E; Milligan G; Ulven T
    J Med Chem; 2017 Jul; 60(13):5638-5645. PubMed ID: 28570808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.
    Christiansen E; Hudson BD; Hansen AH; Milligan G; Ulven T
    J Med Chem; 2016 May; 59(10):4849-58. PubMed ID: 27074625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic.
    Pizzonero M; Dupont S; Babel M; Beaumont S; Bienvenu N; Blanqué R; Cherel L; Christophe T; Crescenzi B; De Lemos E; Delerive P; Deprez P; De Vos S; Djata F; Fletcher S; Kopiejewski S; L'Ebraly C; Lefrançois JM; Lavazais S; Manioc M; Nelles L; Oste L; Polancec D; Quénéhen V; Soulas F; Triballeau N; van der Aar EM; Vandeghinste N; Wakselman E; Brys R; Saniere L
    J Med Chem; 2014 Dec; 57(23):10044-57. PubMed ID: 25380412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3.
    Schmidt J; Smith NJ; Christiansen E; Tikhonova IG; Grundmann M; Hudson BD; Ward RJ; Drewke C; Milligan G; Kostenis E; Ulven T
    J Biol Chem; 2011 Mar; 286(12):10628-40. PubMed ID: 21220428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands.
    Sergeev E; Hansen AH; Pandey SK; MacKenzie AE; Hudson BD; Ulven T; Milligan G
    J Biol Chem; 2016 Jan; 291(1):303-17. PubMed ID: 26518871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Characterization of Fluorescent Probes for the G Protein-Coupled Receptor 35.
    Wei L; Xiang K; Kang H; Yu Y; Fan H; Zhou H; Hou T; Ge Y; Wang J; Guo Z; Chen Y; Zhao Y; Liang X
    ACS Med Chem Lett; 2023 Apr; 14(4):411-416. PubMed ID: 37077394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic.
    Shi ZD; Karki RG; Oishi S; Worthy KM; Bindu LK; Dharmawardana PG; Nicklaus MC; Bottaro DP; Fisher RJ; Burke TR
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1385-8. PubMed ID: 15713392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Potent Tetrazole Free Fatty Acid Receptor 2 Antagonists.
    Valentini A; Schultz-Knudsen K; Højgaard Hansen A; Tsakoumagkou A; Jenkins L; Christensen HB; Manandhar A; Milligan G; Ulven T; Rexen Ulven E
    J Med Chem; 2023 May; 66(9):6105-6121. PubMed ID: 37129317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor binding of NBD-labeled fluorescent estrogens and progestins in whole cells and cell-free preparations.
    Carlson KE; Coppey M; Magdelenat H; Katzenellenbogen JA
    J Steroid Biochem; 1989 Mar; 32(3):345-55. PubMed ID: 2539536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor.
    Hudson BD; Due-Hansen ME; Christiansen E; Hansen AM; Mackenzie AE; Murdoch H; Pandey SK; Ward RJ; Marquez R; Tikhonova IG; Ulven T; Milligan G
    J Biol Chem; 2013 Jun; 288(24):17296-312. PubMed ID: 23589301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligands at the Free Fatty Acid Receptors 2/3 (GPR43/GPR41).
    Milligan G; Bolognini D; Sergeev E
    Handb Exp Pharmacol; 2017; 236():17-32. PubMed ID: 27757758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Specificity and Broad Multitarget Properties of Ligands for the Free Fatty Acid Receptors FFA3/GPR41 and FFA2/GPR43 and the Related Hydroxycarboxylic Acid Receptor HCA2/GPR109A.
    Bisenieks E; Vigante B; Petrovska R; Turovska B; Muhamadejev R; Soloduns V; Velena A; Pajuste K; Saso L; Klovins J; Duburs G; Mandrika I
    Pharmaceuticals (Basel); 2021 Sep; 14(10):. PubMed ID: 34681211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRET- and fluorescence anisotropy-based assays for real-time monitoring of ligand binding to M
    Grätz L; Laasfeld T; Allikalt A; Gruber CG; Pegoli A; Tahk MJ; Tsernant ML; Keller M; Rinken A
    Biochim Biophys Acta Mol Cell Res; 2021 Mar; 1868(3):118930. PubMed ID: 33347921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Activity Relationship Explorations and Discovery of a Potent Antagonist for the Free Fatty Acid Receptor 2.
    Højgaard Hansen A; Christensen HB; Pandey SK; Sergeev E; Valentini A; Dunlop J; Dedeo D; Fratta S; Hudson BD; Milligan G; Ulven T; Rexen Ulven E
    ChemMedChem; 2021 Nov; 16(21):3326-3341. PubMed ID: 34288488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescence- and bioluminescence-based approaches to study GPCR ligand binding.
    Stoddart LA; White CW; Nguyen K; Hill SJ; Pfleger KD
    Br J Pharmacol; 2016 Oct; 173(20):3028-37. PubMed ID: 26317175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Environment-Sensitive Fluorescent Agonists for α
    Qin X; Ma Z; Yang X; Hu S; Chen X; Liang D; Lin Y; Shi X; Du L; Li M
    Anal Chem; 2019 Oct; 91(19):12173-12180. PubMed ID: 31321979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2.
    Lee T; Schwandner R; Swaminath G; Weiszmann J; Cardozo M; Greenberg J; Jaeckel P; Ge H; Wang Y; Jiao X; Liu J; Kayser F; Tian H; Li Y
    Mol Pharmacol; 2008 Dec; 74(6):1599-609. PubMed ID: 18818303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-specific binding of the fluorescent beta-adrenergic receptor probe alprenolol-NBD.
    Rademaker B; Kramer K; van Ingen H; Kranendonk M; Timmerman H
    J Recept Res; 1985; 5(2-3):121-31. PubMed ID: 2993601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids.
    Stoddart LA; Smith NJ; Jenkins L; Brown AJ; Milligan G
    J Biol Chem; 2008 Nov; 283(47):32913-24. PubMed ID: 18801738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of flow cytometric competitive binding protocols and characterization of fluorescently labeled ligands.
    Waller A; Pipkorn D; Sutton KL; Linderman JJ; Omann GM
    Cytometry; 2001 Oct; 45(2):102-14. PubMed ID: 11590622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.